Britain and America have agreed to a key trade agreement that will maintain no duties on British pharmaceutical shipments going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to boost funding on drugs through the public health system. This pledge ensures that duties on these crucial goods will be held at nothing for a timeframe of the next three years.
This deal follows earlier threats to hike import taxes on patented drug products, with increases floated reaching one hundred percent.
"This agreement between the UK reinforces the international landscape for cutting-edge drugs and brings much-needed balance to American-British medicine commerce," a statement noted.
Economic Impact
Pharmaceuticals represent one of the UK's biggest goods shipped to the US, which is easily the primary destination for leading UK drugmakers.
Statistics show that in the 12 months to the end of September, the UK shipped medicines valued at billions to the US. This value represented a significant portion of all goods exports in that period.
"This agreement protects employment, increases funding and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister commented.
Key British Pledges
The deal entails several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to raise overall public funding on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. In the past, repayments exceeded twenty percent.
Recent Tensions
This agreement takes place against a protracted tension between the pharmaceutical industry and the UK government over spending levels and approval rates.
The disagreement were intensified by arguments that American patients were charged a premium for the same drugs than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been directed toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
